The case for treating keratoconus without waiting for disease progression
Articles
Why “acceleration” is the industry keyword for 2024
EXN407 has the potential to be the first topical treatment for diabetic retinopathy and diabetic macular oedema
The study results will help to identify dosing levels for future clinical trials
Working smarter, not harder, to benefit patients
Orbis advances cataract surgery training in low-resource areas with technology
Experts from around the globe converged in San Francisco, California
Austrian investigators recommend an interdisciplinary, rheumatologic–ophthalmologic approach to disease management
Restoration and regeneration represent a new paradigm
A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD
In recognition of global Geographic Atrophy Week, Prevent Blindness is providing free educational resources on GA for patients, care partners and healthcare professionals
At this year’s EURETINA meeting, retina specialists highlighted important developments in diabetic macular oedema and diabetic retinopathy research
Data show transfection in both eyes despite unilateral injection
In early November, the EU MDR issued a CE mark certification for RetInSight’s AI-based geographic atrophy monitor
The carbomer-containing eye gels carry risk of microbial contamination, the regulatory agency warned
Moving toward eliminating drug and chemical safety testing in animals
At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.
Patients who received digital education demonstrated a better understanding of their disease and its management
At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials
Dr Marco Zarbin emphasises the importance of defining “active disease”
In the clinical trial, Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint
Infrastructure across Europe needs a major overhaul to optimise education and patient access in groundbreaking treatments
A patient filed a complaint in June 2019 claiming their medical records had been accessed by an NHS employee
Larger 0.6-mm temporary plug features a tapered edge
Developing technology may offer marked improvements in surgical precision
The company received marketing authorisation approval in the EU earlier this year
The endorsement follows FDA approval in the United States this summer
In this case study, a patient with recently diagnosed cancer demonstrated significant improvement for ocular symptoms of BDUMP following plasmapheresis
Advertisement
Advertisement
